Washington, D.C. – The Medical Imaging & Technology Alliance (MITA), the Council on Radionuclides and Radiopharmaceuticals (CORAR) Inc., and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) today announced that 123 organizations have expressed their support for the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2023 (H.R. 1199/S. 1544). Support for the FIND Act of 2023 comes from a diverse range of organizations, including patient advocacy groups, medical societies, and industry leaders. The legislation is also being considered tomorrow in a House Energy & Commerce Health Subcommittee hearing on improving seniors’ access to innovative drugs, medical devices, and technology.
Diagnostic radiopharmaceuticals enable clinicians to diagnose and treat a wide variety of life-threatening conditions, such as Alzheimer’s & Parkinson’s disease, breast & prostate cancer, heart disease, and neuroendocrine tumors. Unfortunately, Medicare currently bundles payments for this life-saving technology, creating access barriers for patients who need nuclear medicine procedures.
"It’s thrilling to see such widespread support for the FIND Act of 2023," said Patrick Hope, Executive Director of MITA. "This legislation will help ensure that more patients have access to the latest nuclear medicine innovations and technologies."
"We are proud to stand alongside more than 100 organizations in support of the FIND Act, which will help ensure that patients have access to the latest diagnostic nuclear medicine procedures and technologies,” said Helen Nadel, President of the SNMMI.
“With over 100 organizations pledging their support, we continue to build momentum behind improving access to these life-saving technologies for all patients,” said Michael J. Guastella, Executive Director of CORAR. “We look forward to continuing to work alongside lawmakers to improve access through passage of this legislation.”
“When it comes to prostate cancer, men deserve innovative testing and imaging diagnostics for an accurate diagnosis and informed evaluation of disease progression and treatment efficiency,” said Ali Manson, Vice President of Government Relations and Advocacy for ZERO Prostate Cancer. “It is time for Congress to expand access to these procedures and address flawed payment policy through passage of the FIND Act.”
The full list of supporters includes:
- AdMeTech Foundation
- Advanced Accelerator Applications/Novartis
- Aimed Alliance
- Alamo Breast Cancer Foundation
- Alliance for Aging Research
- Alliance for Patient Access
- Alpha-1 Foundation
- Alzheimer’s Association
- Alzheimer’s Los Angeles
- American Behcet’s Disease Association
- American Brain Coalition
- American College of Nuclear Medicine
- American College of Radiology
- American Parkinson Disease Association
- American Society of Radiologic Technologists
- American Society of Neuroradiology
- AnCan Foundation
- Arizona Prostate Cancer Coalition, Inc.
- Autoimmune Association
- Avery’s Hope
- Best Day Ever Foundation
- Biogen
- Blue Earth Diagnostics
- Bracco Diagnostics
- Brian Grant Foundation
- Cancer ABCs
- Carcinoid Cancer Foundation
- Cardinal Health
- Center for Medicine in the Public Interest
- Cervivor
- Clarity Pharmaceuticals
- Colorectal Cancer Alliance
- Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR)
- Curium
- Dallas Area Parkinson Society
- Davis Phinney Foundation
- Diabetes Leadership Council
- Diabetes Patient Advocacy Coalition
- Eckert & Ziegler Isotope Products
- Eckert & Ziegler Radiopharma, Inc.
- Eden Radioisotopes, LLC
- Eli Lilly & Co.
- Eisai
- Friends of Parkinson’s
- FORCE: Facing Hereditary Cancer Empowered
- GE HealthCare
- GO2 Foundation for Lung Cancer
- Hawai’i Parkinson Association
- Healing NET Foundation
- Houston Area Parkinson Society
- ICAN, International Cancer Advocacy Network
- Infusion Providers Alliance
- International Isotopes, Inc.
- Ionetix
- ITM USA, Inc.
- Jubilant Radiopharma
- Learn Advocate Connect: A Neuroendocrine Tumor Society
- Lantheus Holdings, Inc.
- Lewy Body Dementia Association
- Life Molecular Imaging (Formerly Piramal
- Lobular Breast Cancer Alliance
- Looms for Lupus
- Los Angeles Carcinoid Neuroendocrine Tumor Society
- LUNGevity
- Mayo Clinic Department of Radiology
- Medical Imaging &Technology Alliance (MITA)
- MedTrace
- METAvivor
- Michael J. Fox Foundation for Parkinson’s Research
- Michigan Parkinson’s Foundation
- North American Neuroendocrine Tumor Society (NANETS)
- National Alliance for Caregiving
- National Alliance of State Prostate Cancer Coalitions
- National Association of Nuclear Pharmacies
- National Minority Quality Forum
- Navidea Biopharmaceuticals
- Neuroendocrine Tumor Research Foundation
- NorCal CarciNET Community
- Northern California PET
- NorthStar Medical Technologies, LLC
- Northwest Parkinson’s Foundation
- One Cancer Place
- Optimal Tracers
- Parkinson Association of Alabama
- Parkinson Association of the Carolinas
- Parkinson Association of Central Florida
- Parkinson Association of Northern California
- Parkinson Association of the Rockies
- Parkinson’s Foundation
- Parkinson’s Resources of Oregon
- Parkinson & Movement Disorder Alliance
- Parkinson Voice Project
- Patient Empowerment Network
- PD Avengers
- People with Empathy
- PharmaLogic
- Pheo Para Alliance
- Power for Parkinson’s
- Power over Parkinson’s
- Practicing Physicians of America
- Prostate Conditions Education Council
- Prostate Health Education Network
- Rare Access Action Project
- RetireSafe
- Right Scan Right Time
- SHINE Medical Technologies
- Siemens Healthineers
- Society of Nuclear Medicine & Molecular Imaging (SNMMI)
- SOFIE
- Sun Pharmaceutical Industries, Inc.
- SYNGAP1 Foundation
- SSADH Association
- Support for People with Oral Head and Neck Cancer (SPOHNC)
- Telix Pharmaceuticals, Inc.
- TerraPower Isotopes
- Texas Rare Alliance
- ThyCa: Thyroid Cancer Survivors’ Association, Inc.
- Upequity
- Veterans Prostate Cancer Awareness Inc.
- Voices of Alzheimer’s
- Wisconsin Rare Disease Alliance
- Young Survival Coalition
- Zero Prostate Cancer
###